LY3372689

LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase.[1] Its result is to reduce formation of tau protein tangles.

LY3372689
Names
IUPAC name
N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
Identifiers
3D model (JSmol)
  • InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)
    Key: FRVXHWNHGWUTQO-UHFFFAOYSA-N
  • CC(NC1=NC(F)=C(CN2CC[C@H](OCC3=NOC(C)=N3)C[C@@H]2C)S1)=O
Properties
C16H22FN5O3S
Molar mass383.44 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

A molecule containing radioactive fluorine was used with a PET scan to show that LY3372689 binds in the human brain.[2]

Eli Lilly and Company is recruiting subjects for a clinical trial.[3] Some hospitals in Australia: St Vincent's Hospital, SydneyHornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved.[4] Results of the trial are expected by June 2024.[5]

Chemical

The molecule contains three rings: thiazole, piperidine and oxadiazole. Other functional groups included are an ether, acetamide, and a fluoride.[6]

References